ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

iloperidone

Also written as “Iloperidone”, “Iloperidone 1 MG” and “iloperidone (oral tablet)”.

Its studies are mostly in Schizophrenia · Hypertension · Parkinson Disease, led by 4 companies.

Drug pageIloperidone: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 5, 202215 company-led studies, 3 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticals103 open or runningphase 4since Dec 5, 2022Nov 10, 2005Nov 2027phase 3 · NCT06961968
CSPC Pharmaceutical Groupits history only20 open or runningphase 3since May 19, 2015May 19, 2015none ahead
Novartisits history only20 open or runningphase 4since Sep 19, 2010Sep 19, 2010none ahead
Hansoh Pharmaceutical Groupits history only10 open or runningphase 2since Jun 17, 2012Jun 17, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vanda Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2005First study: phase 3 study in SchizophreniaFirst studyNCT00254202 · 593 enrolled · United States, India
  2. Feb 3, 2011Phase 3 study in SchizophreniaNCT01291511 · 635 enrolled · United States, India, Ukraine
  3. Aug 31, 2011Phase 1 study in SchizophreniaNCT01495169 · 33 enrolled · United States
  4. Oct 7, 2019Phase 1 study in SchizophreniaNCT04127058 · 12 enrolled · United States
  5. Jan 13, 2021Phase 1 study in SchizophreniaNCT04712734 · 42 enrolled · United States
  6. Mar 24, 2021Phase 3 study in Bipolar I DisorderNCT04819776 · 417 enrolled · United States, Bulgaria, Poland
  7. Apr 18, 2022Phase 2 study in Parkinson Disease PsychosisNCT05344365 · United States
  8. Dec 5, 2022Phase 4 study in SchizophreniaNCT05648591 · 100 planned · United States
  9. Apr 29, 2025Phase 3 study in SchizophreniaNCT06961968 · 400 planned · United States
  10. Jul 22, 2025Phase 2 study in HypertensionNCT07090161 · 240 planned · United States
  11. Oct 1, 2026Primary completion moved from 2026-03-31 to 2028-12-31Date moved laterphase 4 · +33 months · NCT05648591

Ahead

  1. Nov 2027Primary completion: phase 3 study in SchizophreniaNCT06961968
  2. Dec 31, 2028Primary completion: phase 4 study in SchizophreniaNCT05648591

TargetBeta

DRD2 →HTR2A →read by rule
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
lurasidoneruleSumitomo Pharmaphase 452
lumateperoneruleJohnson & Johnsonphase 325

Studies

All 10 Vanda Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07090161Hypertension · United States2RecruitingOct 2026240
NCT06961968Schizophrenia · United States3RecruitingNov 2027400
NCT05648591Schizophrenia · United States4RecruitingDec 31, 2028100
NCT05344365Parkinson Disease Psychosis · United States2WithdrawnNov 20230
NCT04819776Bipolar I Disorder · United States, Bulgaria, Poland3CompletedSep 7, 2022417
NCT04712734Schizophrenia · United States1CompletedAug 30, 202242
NCT04127058Schizophrenia · United States1CompletedNov 27, 201912
NCT01495169Schizophrenia · United States1CompletedFeb 201533
NCT01291511Schizophrenia · United States, India, Ukraine3CompletedMar 2014635
NCT00254202Schizophrenia · United States, India3CompletedSep 26, 2006593

How it is read

Names in the registry

  • “Iloperidone”, 9 entries
  • “iloperidone”, 4 entries
  • “Iloperidone 1 MG”, 1 entry
  • “iloperidone (oral tablet)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.